Volume 12, Number 4—April 2006
Economic Impact of Lyme Disease
|Diagnosis group‡||Cohort||No.||Indirect medical cost (US$)§
||Nonmedical cost (US$)¶
||Productivity loss (US$)#
*Indirect medical costs, nonmedical costs, and productivity losses were acquired from patient questionnaire (1997–1998).
†All costs were converted to 2000 equivalent.
‡Patients were divided into 5 diagnosis groups: clinically defined early-stage LD, clinically defined late-stage LD, suspected LD, tick bite, and other related complaints.
§Indirect medical costs refer to prescription and nonprescription drug costs patients paid out of pocket.
¶Nonmedical costs are payments made for home/health aides and miscellaneous services, such as transportation and babysitting.
#Productivity losses refer to losses in earning due to illness.
**SD, standard deviation.
1Current affiliation: Maryland Department of Health and Mental Hygiene, Baltimore, Maryland, USA